American Association for Cancer Research
Browse
00085472can101030-sup-sfig_1.pdf (48.07 kB)

Supplementary Figure 1 from Phase I Assessment of New Mechanism-Based Pharmacodynamic Biomarkers for MLN8054, a Small-Molecule Inhibitor of Aurora A Kinase

Download (48.07 kB)
journal contribution
posted on 2023-03-30, 20:03 authored by Arijit Chakravarty, Vaishali Shinde, Josep Tabernero, Andres Cervantes, Roger B. Cohen, E. Claire Dees, Howard Burris, Jeffrey R. Infante, Teresa Macarulla, Elena Elez, Jordi Andreu, Edith Rodriguez-Braun, Susana Rosello, Margaret von Mehren, Neal J. Meropol, Corey J. Langer, Bert ONeil, Douglas Bowman, Mengkun Zhang, Hadi Danaee, Laura Faron-Yowe, Gary Gray, Hua Liu, Jodi Pappas, Lee Silverman, Chris Simpson, Bradley Stringer, Stephen Tirrell, Ole Petter Veiby, Karthik Venkatakrishnan, Katherine Galvin, Mark Manfredi, Jeffrey A. Ecsedy
Supplementary Figure 1 from Phase I Assessment of New Mechanism-Based Pharmacodynamic Biomarkers for MLN8054, a Small-Molecule Inhibitor of Aurora A Kinase

History

ARTICLE ABSTRACT

The mitotic kinase Aurora A is an important therapeutic target for cancer therapy. This study evaluated new mechanism-based pharmacodynamic biomarkers in cancer patients in two phase I studies of MLN8054, a small-molecule inhibitor of Aurora A kinase. Patients with advanced solid tumors received MLN8054 orally for 7 consecutive days in escalating dose cohorts, with skin and tumor biopsies obtained before and after dosing. Skin biopsies were evaluated for increased mitotic cells within the basal epithelium. Tumor biopsies were assessed for accumulation of mitotic cells within proliferative tumor regions. Several patients in the highest dose cohorts showed marked increases in the skin mitotic index after dosing. Although some tumors exhibited increases in mitotic cells after dosing, others displayed decreases, a variable outcome consistent with dual mechanisms of mitotic arrest and mitotic slippage induced by antimitotics in tumors. To provide a clearer picture, mitotic cell chromosome alignment and spindle bipolarity, new biomarkers of Aurora A inhibition that act independently of mitotic arrest or slippage, were assessed in the tumor biopsies. Several patients, primarily in the highest dose cohorts, had marked decreases in the percentage of mitotic cells with aligned chromosomes and bipolar spindles after dosing. Evidence existed for an exposure–effect relationship for mitotic cells with defects in chromosome alignment and spindle bipolarity that indicated a biologically active dose range. Outcomes of pharmacodynamic assays from skin and tumor biopsies were concordant in several patients. Together, these new pharmacodynamic assays provide evidence for Aurora A inhibition by MLN8054 in patient skin and tumor tissues. Cancer Res; 71(3); 675–85. ©2010 AACR.